Pulmonary fibrosis secondary to COVID-19: a narrative review
Autor: | Alexandre Todorovic Fabro, Bruno Guedes Baldi, Carlos Gustavo Yuji Verrastro, Suzana Erico Tanni, Andre Luiz Pereira de Albuquerque, Sergio Marrone Ribeiro, Eloara V.M. Ferreira, Marcio Valente Yamada Sawamura |
---|---|
Rok vydání: | 2021 |
Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Databases Factual Pulmonary Fibrosis MEDLINE Disease Cochrane Library Severity of Illness Index Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Risk Factors Pulmonary fibrosis medicine Humans Immunology and Allergy 030212 general & internal medicine Intensive care medicine Lung SARS-CoV-2 business.industry Public Health Environmental and Occupational Health Interstitial lung disease COVID-19 medicine.disease medicine.anatomical_structure 030228 respiratory system Disease Progression Etiology Differential diagnosis Tomography X-Ray Computed business |
Zdroj: | Expert Review of Respiratory Medicine. 15:791-803 |
ISSN: | 1747-6356 1747-6348 |
DOI: | 10.1080/17476348.2021.1916472 |
Popis: | Introduction: Coronavirus disease 2019 (COVID-19) is still increasing worldwide, and as a result, the number of patients with pulmonary fibrosis secondary to COVID-19 will expand over time. Risk factors, histopathological characterization, pathophysiology, prevalence, and management of post-COVID-19 pulmonary fibrosis are poorly understood, and few studies have addressed these issues.Areas covered:This article reviews the current evidence regarding post-COVID-19 pulmonary fibrosis, with an emphasis on the potential risk factors, histopathology, pathophysiology, functional and tomographic features, and potential therapeutic modalities. A search on the issue was performed in the MEDLINE, Embase, and SciELO databases and the Cochrane library between 1 December 2019, and 25 January 2021. Studies were reviewed and relevant topics were incorporated into this narrative review. Expert opinion: Pulmonary sequelae may occur secondary to COVID-19, which needs to be included as a potential etiology in the current differential diagnosis of pulmonary fibrosis. Therefore, serial clinical, tomographic, and functional screening for pulmonary fibrosis is recommended after COVID-19, mainly in patients with pulmonary involvement in the acute phase of the disease. Further studies are necessary to determine the risk factors, markers, pathophysiology, and appropriate management of post-COVID-19 pulmonary fibrosis. |
Databáze: | OpenAIRE |
Externí odkaz: |